Myriad Genetics (MYGN) News Today $15.12 -0.18 (-1.18%) (As of 11/21/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Natixis Advisors LLC Acquires 44,646 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN)Natixis Advisors LLC lifted its holdings in shares of Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 16.2% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 320,013 shares of the company's stock after purchasing an additional 44,646 sharesNovember 22 at 3:40 AM | marketbeat.comMyriad Genetics (NASDAQ:MYGN) Given New $21.00 Price Target at Morgan StanleyNovember 21 at 5:47 AM | americanbankingnews.comMyriad Genetics Expands Partnership with Illumina to Enhance Genomic Profiling for Cancer DetectionNovember 20 at 6:04 PM | quiverquant.comMyriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina's Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2November 20 at 4:30 PM | globenewswire.comMyriad Genetics (NASDAQ:MYGN) Lowered to Hold Rating by StockNews.comStockNews.com cut shares of Myriad Genetics from a "buy" rating to a "hold" rating in a research report on Wednesday.November 20 at 3:13 AM | marketbeat.comMyriad announces Prequel Prenatal Screening can be performed at 8 weeksNovember 19 at 2:41 PM | markets.businessinsider.comMyriad Genetics (NASDAQ:MYGN) Reaches New 1-Year Low After Analyst DowngradeMyriad Genetics (NASDAQ:MYGN) Sets New 52-Week Low on Analyst DowngradeNovember 19 at 11:21 AM | marketbeat.comMyriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into PregnancyNovember 19 at 9:40 AM | markets.businessinsider.comMyriad Genetics price target lowered to $21 from $32 at Morgan StanleyNovember 19 at 4:40 AM | markets.businessinsider.comMorgan Stanley Has Lowered Expectations for Myriad Genetics (NASDAQ:MYGN) Stock PriceMorgan Stanley reduced their price objective on Myriad Genetics from $32.00 to $21.00 and set an "equal weight" rating on the stock in a report on Monday.November 18, 2024 | marketbeat.com71,739 Shares in Myriad Genetics, Inc. (NASDAQ:MYGN) Bought by State of New Jersey Common Pension Fund DState of New Jersey Common Pension Fund D purchased a new position in shares of Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 71,739 shares of the company's stock, valued at approximately $1,96November 18, 2024 | marketbeat.comMYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Myriad Genetics, Inc. and Encourages Investors to Contact the FirmNovember 17, 2024 | globenewswire.com173,626 Shares in Myriad Genetics, Inc. (NASDAQ:MYGN) Purchased by Simplify Asset Management Inc.Simplify Asset Management Inc. purchased a new position in Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 173,626 shares of the company's stock, valued at approximately $4,756,0November 15, 2024 | marketbeat.comMYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Myriad Genetics, Inc. and Encourages Investors to Contact the FirmNovember 14, 2024 | businesswire.comMyriad Genetics price target lowered to $24 from $34 at ScotiabankNovember 14, 2024 | markets.businessinsider.comMyriad Genetics (MYGN) Gets a Buy from ScotiabankNovember 14, 2024 | markets.businessinsider.comMYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Myriad Genetics, Inc. and Encourages Investors to Contact the FirmNovember 13, 2024 | prnewswire.comMyriad Genetics price target lowered to $24 from $30 at Piper SandlerNovember 12, 2024 | markets.businessinsider.comMYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Myriad Genetics, Inc. and Encourages Investors to Contact the FirmNovember 11, 2024 | globenewswire.comMyriad Genetics: Overcoming Setbacks with Strategic Resilience and Growth ProspectsNovember 11, 2024 | markets.businessinsider.comMyriad Genetics (NASDAQ:MYGN) Price Target Cut to $24.00 by Analysts at Piper SandlerPiper Sandler decreased their price objective on Myriad Genetics from $30.00 to $24.00 and set a "neutral" rating on the stock in a report on Monday.November 11, 2024 | marketbeat.comMyriad Genetics, Inc. (MYGN) Q3 2024 Earnings Call TranscriptNovember 9, 2024 | seekingalpha.comMyriad Genetics Reports Solid Q3 2024 Growth Amid ChallengesNovember 9, 2024 | markets.businessinsider.comMyriad Genetics reports Q3 adjusted EPS 6c, consensus 2cNovember 8, 2024 | markets.businessinsider.comMyriad Genetics Inc (MYGN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Policy ...November 8, 2024 | finance.yahoo.comMyriad Genetics Inc. Q3 Earnings SummaryNovember 8, 2024 | markets.businessinsider.comQ3 2024 Myriad Genetics Inc Earnings Call TranscriptNovember 8, 2024 | gurufocus.comMyriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial GuidanceNovember 7, 2024 | globenewswire.comMYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Myriad Genetics, Inc. and Encourages Investors to Contact the FirmNovember 6, 2024 | prnewswire.comMyriad Genetics comments on UnitedHealthcare’s updated policyNovember 5, 2024 | markets.businessinsider.comMyriad Genetics in Active Talks with UnitedHealthcare to Keep Coverage of GeneSightNovember 4, 2024 | marketwatch.comMyriad Genetics Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic TestingNovember 4, 2024 | markets.businessinsider.comTD Cowen Reaffirms Their Hold Rating on Myriad Genetics (MYGN)November 4, 2024 | markets.businessinsider.comMyriad Genetics (NASDAQ:MYGN) Shares Down 4.6% - Here's WhyMyriad Genetics (NASDAQ:MYGN) Shares Down 4.6% - Here's WhyNovember 4, 2024 | marketbeat.comMyriad Genetics Comments on UnitedHealthcare's Updated Medical Policy for Pharmacogenetic TestingNovember 4, 2024 | globenewswire.comUnitedHealth update ‘not the end’ for Myriad’s GeneSight, says Raymond JamesNovember 3, 2024 | markets.businessinsider.comMyriad Genetics Shares Slip 21% on UnitedHealthcare Coverage ChangesNovember 2, 2024 | marketwatch.comPiper says Myriad appears to be trading down on GeneSight coverage changeNovember 2, 2024 | markets.businessinsider.comMyriad weakness due to UnitedHealth coverage update, says StephensNovember 2, 2024 | markets.businessinsider.comMyriad Genetics, Inc. (NASDAQ:MYGN) Given Consensus Rating of "Hold" by AnalystsMyriad Genetics, Inc. (NASDAQ:MYGN - Get Free Report) has received a consensus recommendation of "Hold" from the twelve ratings firms that are presently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, three have given a hold rating and sevenNovember 2, 2024 | marketbeat.comMyriad Genetics (NASDAQ:MYGN) Shares Gap Down - What's Next?Myriad Genetics (NASDAQ:MYGN) Shares Gap Down - Here's What HappenedNovember 1, 2024 | marketbeat.comMyriad Genetics (MYGN) to Release Earnings on ThursdayMyriad Genetics (NASDAQ:MYGN) will be releasing earnings after the market closes on Thursday, November 7, Zacks reports.October 31, 2024 | marketbeat.comMyriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024October 30, 2024 | globenewswire.comAssenagon Asset Management S.A. Sells 83,291 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN)Assenagon Asset Management S.A. trimmed its holdings in shares of Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 33.2% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 167,233 shares of the company's stock after selling 8October 30, 2024 | marketbeat.comOmniStar Financial Group Inc. Makes New $863,000 Investment in Myriad Genetics, Inc. (NASDAQ:MYGN)OmniStar Financial Group Inc. acquired a new stake in Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 31,506 shares of the company's stock, valued at aOctober 18, 2024 | marketbeat.comMyriad Genetics and jscreen™ Announce Strategic Partnership to Advance Health Equity and Genetic Testing AccessOctober 17, 2024 | markets.businessinsider.com21,968 Shares in Myriad Genetics, Inc. (NASDAQ:MYGN) Bought by Sanctuary Advisors LLCSanctuary Advisors LLC acquired a new stake in shares of Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 21,968 shares of the company's stock, valued at approximately $537,000. A number of otheOctober 16, 2024 | marketbeat.comMyriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record IntegrationOctober 15, 2024 | globenewswire.comMyriad Genetics (NASDAQ:MYGN) shareholders are still up 61% over 1 year despite pulling back 7.9% in the past weekOctober 15, 2024 | finance.yahoo.comSG Americas Securities LLC Takes $649,000 Position in Myriad Genetics, Inc. (NASDAQ:MYGN)SG Americas Securities LLC bought a new stake in shares of Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 23,678 shares of the company's stock, valued at apprOctober 14, 2024 | marketbeat.com Get Myriad Genetics News Delivered to You Automatically Sign up to receive the latest news and ratings for MYGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Democrats Sold Out the American Dream - Are you ready? (Ad)There's a massive housing crisis looming, and nobody on Main Street knows it yet... The Democrats sold out the American Dream - and now, millions of Americans are locked out of the housing market, forced to become "permanent renters." Click here to see exactly what you need to do >>> MYGN Media Mentions By Week MYGN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MYGN News Sentiment▼0.140.48▲Average Medical News Sentiment MYGN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MYGN Articles This Week▼145▲MYGN Articles Average Week Get Myriad Genetics News Delivered to You Automatically Sign up to receive the latest news and ratings for MYGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies NTLA News QDEL News NEOG News IONS News ALKS News FOLD News GERN News LGND News MNKD News CLDX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MYGN) was last updated on 11/22/2024 by MarketBeat.com Staff From Our PartnersFinancial Prophecy The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredBuffett Dumps $982 Million in BofA Stock—What Does He Know?Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track reco...Genesis Gold Group | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredTrump’s First Warning: 'Boneheads' at the Fed Could Drain Your WealthTrump is Back, but The FED is still coming for Your Wallet. While he’s pushing for America’s growth, the F...All American Assets | SponsoredCentral Bank Abandons USDYou know what doesn't care about elections? Gold. If you want to protect your savings & retirement from our...Desko Digital | SponsoredAmerica’s Pro-Crypto AgendaCash In On the Pro-Crypto America 27 experts reveal their top picks for 2025 Crypto 101 Media | SponsoredA “Thank You Gift” From Pres. Trump - GeniusThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Myriad Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Myriad Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free mygn Stock Alerts